U.S. Markets closed

uniQure N.V. (QURE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
37.53-0.55 (-1.44%)
At close: 4:00PM EST

uniQure N.V.

Paasheuvelweg 25a
Amsterdam 1105 BP
Netherlands
31 20 240 6000
http://www.uniqure.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees248

Key Executives

NameTitlePayExercisedYear Born
Mr. Matthew Craig KapustaCEO, CFO & Exec. Director908.63k459.12k1972
Dr. Alexander E. Kuta Ph.D.Exec. VP of Operations610.61k2.42M1960
Prof. Hugo KatusChairman of Scientific Advisory Board and Managing Director of UniQure-GermanyN/AN/AN/A
Mr. Christian KlemtChief Accounting OfficerN/AN/A1973
Mr. David CervenyChief Legal Officer, Gen. Counsel & Sec.N/AN/A1967
Ms. Maria E. CantorChief Communications OfficerN/AN/A1968
Dr. Tamara Tugal Ph.D., MBABus. Devel. DirectorN/AN/AN/A
Mr. James BradyChief HR OfficerN/AN/AN/A
Mr. Jonathan Garen M.S.Chief Bus. OfficerN/AN/A1966
Mr. Ricardo Dolmetsch Ph.D.Pres of R&DN/AN/A1969
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment of hemophilia A; and AMT-190, an IV-administered adeno-associated virus 5-based gene therapy for the treatment of Fabry disease. In addition, it engages in developing AMT-150, a gene therapy candidate for the treatment of Spinocerebellar Ataxia Type 3 disease. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Corporate Governance

uniQure N.V.’s ISS Governance QualityScore as of December 1, 2020 is 2. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 3; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.